Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBIO Catalyst Biosciences		$0.77	$0.19 ▼ $8.69	$291.29M	1.05	763,526 shs	32,246 shs
EYEN Eyenovia	$0.53 -1.8%	$1.37	$0.50 ▼ $5.85	$25.56M	1.64	1.55 million shs	575,049 shs
IMNM Immunome	$17.18 -1.2%	$23.03	$4.44 ▼ $30.96	$1.04B	1.66	629,539 shs	852,654 shs
MACK Merrimack Pharmaceuticals	$14.68	$14.68	$11.53 ▼ $15.89	$213.33M	1.43	119,209 shs	113,575 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBIO Catalyst Biosciences	0.00%	0.00%	0.00%	0.00%	+3,136.08%
EYEN Eyenovia	-1.56%	-10.32%	-54.82%	-65.53%	-88.18%
IMNM Immunome	-1.15%	-18.27%	-28.65%	+27.26%	+209.55%
MACK Merrimack Pharmaceuticals	0.00%	-0.34%	-0.07%	+11.21%	+18.39%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EYEN Eyenovia	0.7532 of 5 stars	3.5	1.0	0.0	0.0	0.6	1.7	0.0
IMNM Immunome	1.6108 of 5 stars	3.5	0.0	0.0	0.0	3.2	1.7	0.0
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A
EYEN Eyenovia	3.00	Buy	$10.00	1,783.59% Upside
IMNM Immunome	3.00	Buy	$32.67	90.14% Upside
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest EYEN, IMNM, CBIO, and MACK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	IMNM Immunome	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
4/1/2024	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$27.00 ➝ $33.00
3/19/2024	EYEN Eyenovia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
3/6/2024	EYEN Eyenovia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
1/29/2024	IMNM Immunome	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
1/29/2024	IMNM Immunome	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
1/23/2024	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $19.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBIO Catalyst Biosciences	$790K	0.00	N/A	N/A	($0.78) per share	0.00
EYEN Eyenovia	N/A	N/A	N/A	N/A	$0.20 per share	N/A
IMNM Immunome	$14.02M	73.14	N/A	N/A	$2.77 per share	6.20
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBIO Catalyst Biosciences	-$8.24M	-$1.38	N/A	N/A	N/A	N/A	-364.68%	-281.68%	N/A
EYEN Eyenovia	-$27.26M	-$0.67	N/A	N/A	N/A	N/A	-213.33%	-89.16%	5/9/2024 (Estimated)
IMNM Immunome	-$106.81M	-$5.39	N/A	N/A	N/A	-761.92%	-69.74%	-31.40%	5/3/2024 (Estimated)
MACK Merrimack Pharmaceuticals	-$1.18M	-$0.08	N/A	∞	N/A	N/A	-6.24%	-6.09%	5/2/2024 (Estimated)

Latest EYEN, IMNM, CBIO, and MACK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/18/2024	Q4 2023	EYEN Eyenovia	-$0.17	-$0.17	N/A	-$0.18	$0.50 million	N/A
3/7/2024	Q4 2023	MACK Merrimack Pharmaceuticals	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A	N/A
EYEN Eyenovia	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBIO Catalyst Biosciences	N/A	2.88	2.88
EYEN Eyenovia	1.00	2.17	2.16
IMNM Immunome	N/A	6.63	6.63
MACK Merrimack Pharmaceuticals	N/A	43.50	43.50

Ownership

Institutional Ownership

Company	Institutional Ownership
CBIO Catalyst Biosciences	5.98%
EYEN Eyenovia	25.84%
IMNM Immunome	44.58%
MACK Merrimack Pharmaceuticals	63.97%

Insider Ownership

Company	Insider Ownership
CBIO Catalyst Biosciences	2.92%
EYEN Eyenovia	7.80%
IMNM Immunome	20.00%
MACK Merrimack Pharmaceuticals	28.87%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CBIO Catalyst Biosciences	7	37.98 million	36.87 million	Optionable
EYEN Eyenovia	57	47.39 million	43.69 million	Optionable
IMNM Immunome	37	59.69 million	47.76 million	Optionable
MACK Merrimack Pharmaceuticals	426	14.53 million	10.34 million	Optionable

EYEN, IMNM, CBIO, and MACK Headlines

Source	Headline
	From debilitating disease to the marathon eagletribune.com - April 14 at 6:48 AM
	Merrimack Pharmaceuticals (NASDAQ:MACK) and Seelos Therapeutics (NASDAQ:SEEL) Critical Comparison americanbankingnews.com - April 13 at 1:44 AM
	Diagonal starts up with $128M to make better ‘activator’ antibody drugs finance.yahoo.com - April 3 at 4:07 PM
	Merrimack Receives $225 Million Milestone Payment from Ipsen businesswire.com - March 27 at 4:30 PM
	Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above 200 Day Moving Average of $13.19 marketbeat.com - March 26 at 4:11 AM
	Here are chances Dalton Knecht, Tennessee basketball will be in Memphis for March Madness tennessean.com - March 12 at 10:27 AM
	Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts msn.com - March 8 at 3:41 PM
	MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023 investorplace.com - March 8 at 10:02 AM
	Merrimack Reports Full Year 2023 Financial Results businesswire.com - March 7 at 4:30 PM
	Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company finance.yahoo.com - March 4 at 7:39 AM
	Merrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, Predictions benzinga.com - February 22 at 12:38 PM
	Unlocking The Potentials Of Liposomal Drug Delivery Device Market opprairie.com - February 20 at 2:37 AM
	MACK Mar 2024 14.000 put finance.yahoo.com - February 17 at 7:50 PM
	MACK Mar 2024 4.000 put finance.yahoo.com - February 17 at 2:49 PM
	OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer markets.businessinsider.com - February 15 at 1:03 PM
	Merrimack to call it a day after pocketing Ipsen cash thepharmaletter.com - February 15 at 8:02 AM
	MACK Feb 2024 16.000 put finance.yahoo.com - February 14 at 8:47 PM
	FDA Approves New First-Line Med for Pancreatic Cancer as Drug’s Initial Developer Dissolves medcitynews.com - February 14 at 8:47 PM
	Ipsen drug approved by FDA for early pancreatic cancer finance.yahoo.com - February 14 at 3:42 PM
	The S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cuts msn.com - February 13 at 7:31 PM
	Merrimack Pharmaceuticals to Hold Meeting on Corporate Dissolution marketwatch.com - February 13 at 7:31 PM
	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) finance.yahoo.com - February 13 at 7:31 PM
	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) businesswire.com - February 13 at 4:18 PM
	Investing in Merrimack Pharmaceuticals Inc (MACK): What You Must Know knoxdaily.com - January 1 at 10:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Catalyst Biosciences

NASDAQ:CBIO

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Eyenovia

NASDAQ:EYEN

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Immunome

NASDAQ:IMNM

Immunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Merrimack Pharmaceuticals

NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial